publication date: Nov. 9, 2018

Clinical Roundup

Stereotactic radiosurgery and surgical resection offer similar local control of brain metastases

Stereotactic radiosurgery offered results comparable to surgery in controlling local brain metastases, Fox Chase Cancer Center researchers have found.

The study was produced in collaboration with European Organization for the Research and Treatment of Cancer. It is the largest direct comparison of the two treatment modalities. The paper appears in JAMA Oncology.

Researchers analyzed 268 patients who received either surgery or SRS— focal, high-dose, precisely targeted radiation. They report that early local control of treated lesions was better with SRS compared to those treated surgically, although the relative benefit decreased with time.

“Risk of early local recurrence was higher among surgical patients, while risk of late relapse was higher among SRS patients,” said Stephanie Weiss, chief of the Division of Neurological Oncology at Fox Chase, and author of the study.

She said while nine months post-treatment, the risk of recurrence was slightly higher among patients who had received SRS, nevertheless at 2-years, actual local control after SRS remained equal to or better than that of surgery.

The authors presented an early version of this study at the annual meeting of the American Society for Therapeutic Radiology and Oncology in September 2017. It was chosen for distinction at the “Scientific Highlights” program, emphasizing high-scoring and high-impact work.

This publication was supported by grant number P30 CA006927 from the National Cancer Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI or the National Institutes of Health.


Trisalus pressure-enabled drug delivery increased effect of anti-CEA CAR-T in pancreatic … Continue reading Stereotactic radiosurgery and surgical resection offer similar local control of brain metastases

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.